Patents and Other Intellectual Property Rights

CS MEDICA holds solid IPR protection, in a market with high barriers to entry, and a collaborative approach to innovation, while documenting efficacy and building trust through the Clinical Information management system (CIM) collecting post-marketing clinical test results in collaboration with distributors in local markets. 


CS MEDICA strives towards granting patent acceptance on all present and future treatment products. All CS MEDICA’s treatment products (topical and intranasal products) as of today are patented in accordance with PCT (Patent Cooperation Treaty) covering 153 nations across the globe. The Company currently has seven proceeding patents that are filed and pending. The patents pending are summarized below. 

The Company currently has seven proceeding patents that are filed and pending. The patents pending are summarized below.


In the scenario where the patents above are granted, the Company will have a total of 16 patented products, including: the Psoriasis gel and the Psoriasis food supplement, the Arthritis gel and the Arthritis supplement, the Anti-hair loss serum and the Anti-hair loss supplement, the Sports Gel 650, the Sports Gel 1000, VET Pain Arthritis gel,  the Wound gel, the VET HOT Spot Gel, the VET MUCK Gel,  the Protective nasal gel, the Sleep nasal spray, the Pain patch and the VET Pain Patch. 

The patents are intended to strengthen the protection of the Company’s products. If granted, the patents will protect the technology to 2039 (patent filed in 2019) and 2041 (patents filed in 2021). The timelines state that before August 2025 for Arthritis and Psoriasis gel and 2027 for the last products, a national process should be in place, meaning the Company needs to determine in which countries and/or regions CS MEDICA intend to file the patent including all formalities. It is the current strategy to extend this protection worldwide, such as in the US, China, Europe, and the rest of the world.


Further, we protect our IPR by global trademarks registration in class 03, 05, and 10 – covering the following territories: EU, Switzerland, Norway, India, and the following territories applied and pending; the USA, Canada, China, South Korea, Thailand, Japan, Vietnam, Indonesia, Australia, New Zealand Argentina, Brazil, Chile, Japan, Korea, Malaysia, and Vietnam.

Digital Solutions

As a pioneer in the Cannabis market, we have stepped into a role of an active provider of relevant information and research data regarding cannabinoids and their properties to the wide public. We have developed digital solutions, which still are not common in the medical industry but crucial for our go-to-market strategy.

An Open Access Repository System dedicated to the investigation of cannabionoids and cannabionoids-based therapies is inaugurated at the brand site ( The OARS is an open-source system available to the public and is intended to provide and share all recent clinical test results, studies, journal publications and a variety of other educational resources within pain and autoimmune-related disorders. The OARS, currently covering 60 diseases, will be crucial for the research and development and in the implementation of the go-to-market strategy as a help the consumers to understand the benefits using cannabinoids in treatment. The OARS are keept up to date through monitoring online publications, where selected combinations of keywords are set up in a semantic market monitoring system (SMMS).

Our SMMS are based on the program; Rankur, a search machine, which is analogical to other search engines with one difference – it spots important web sites for our saved keywords and monitors them in real time. Our SMMS is the first to detect new mentions on the web. The SMMS web crawler reads more than 30’000’000 pages per day. Semantic monitoring will take place in the languages/markets we represent in our Go-To-Market strategy.

Together with our Product Information Portal (PIM) and Clinical Information Management system (CIM), great value is added to the collaboration between CS medica and our distributor. Both portals, available for us and our partners, will reduce manual workload, increase roll-out speed, and ensure the same level of quality to stakeholders in all locations. Moreover, the CIM will allow us as well as our distributors to perform post-marketing clinical trials in collaboration with local organizations, such as arthritis and psoriasis organizations. This facility ensures optimal local knowledge sharing via the organizations representing the factual disease profile.

The brandsite,, is currently available in English, Danish, Swedish, and German. The local translation follows as CS MEDICA penetrates each country, supporting local distributors with the Company’s CANNASEN® store locator, linking to local online and physical stores.